摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-{[3-chloro-5-methyl-3'-({[3-(4-morpholinyl) propyl]amino}methyl) [1,1'-biphenyl]-4-yl]amino}-7-[3-({[3-(4-morpholinyl) propyl]amino}methyl) phenyl]-3-quinolinecarbonitrile | 364791-53-7

中文名称
——
中文别名
——
英文名称
4-{[3-chloro-5-methyl-3'-({[3-(4-morpholinyl) propyl]amino}methyl) [1,1'-biphenyl]-4-yl]amino}-7-[3-({[3-(4-morpholinyl) propyl]amino}methyl) phenyl]-3-quinolinecarbonitrile
英文别名
4-[2-Chloro-6-methyl-4-[3-[(3-morpholin-4-ylpropylamino)methyl]phenyl]anilino]-7-[3-[(3-morpholin-4-ylpropylamino)methyl]phenyl]quinoline-3-carbonitrile
4-{[3-chloro-5-methyl-3'-({[3-(4-morpholinyl) propyl]amino}methyl) [1,1'-biphenyl]-4-yl]amino}-7-[3-({[3-(4-morpholinyl) propyl]amino}methyl) phenyl]-3-quinolinecarbonitrile化学式
CAS
364791-53-7
化学式
C45H52ClN7O2
mdl
——
分子量
758.407
InChiKey
JFMUCLXEPXRVTJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    7
  • 重原子数:
    55
  • 可旋转键数:
    16
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    97.7
  • 氢给体数:
    3
  • 氢受体数:
    9

文献信息

  • 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS
    申请人:Wyeth
    公开号:EP1268431B1
    公开(公告)日:2007-08-29
  • 3-Cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
    申请人:Wyeth
    公开号:US20040176602A1
    公开(公告)日:2004-09-09
    This invention provides compounds of Formula (I), having the structure 1 where T, Z, X, A, R 1 , R 2a , R 2b , R 2c , R 3 , R 4 , and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.
  • PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR
    申请人:Zacharchuk Charles Michael
    公开号:US20100069340A1
    公开(公告)日:2010-03-18
    This invention is directed to a pharmaceutical composition comprising an Src kinase inhibitor and an aromatase inhibitor, and to the use of a combination of an Src kinase inhibitor and an aromatase inhibitor in treating abnormal cell proliferation and abnormal angiogenesis associated with cancer, including breast cancer.
  • US6521618B2
    申请人:——
    公开号:US6521618B2
    公开(公告)日:2003-02-18
  • US6689772B1
    申请人:——
    公开号:US6689772B1
    公开(公告)日:2004-02-10
查看更多